[go: up one dir, main page]

AU2001266767A1 - RTVP based compositions and methods for the treatment of prostate cancer - Google Patents

RTVP based compositions and methods for the treatment of prostate cancer

Info

Publication number
AU2001266767A1
AU2001266767A1 AU2001266767A AU6676701A AU2001266767A1 AU 2001266767 A1 AU2001266767 A1 AU 2001266767A1 AU 2001266767 A AU2001266767 A AU 2001266767A AU 6676701 A AU6676701 A AU 6676701A AU 2001266767 A1 AU2001266767 A1 AU 2001266767A1
Authority
AU
Australia
Prior art keywords
polypeptide
rtvp
nucleic acid
prostate cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266767A
Other languages
English (en)
Inventor
Chengzhen Ren
Timothy C. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU2001266767A1 publication Critical patent/AU2001266767A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001266767A 2000-06-08 2001-06-08 RTVP based compositions and methods for the treatment of prostate cancer Abandoned AU2001266767A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20998900P 2000-06-08 2000-06-08
US60/209,989 2000-06-08
PCT/US2001/018487 WO2002006344A2 (fr) 2000-06-08 2001-06-08 Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique

Publications (1)

Publication Number Publication Date
AU2001266767A1 true AU2001266767A1 (en) 2002-01-30

Family

ID=22781163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266767A Abandoned AU2001266767A1 (en) 2000-06-08 2001-06-08 RTVP based compositions and methods for the treatment of prostate cancer

Country Status (7)

Country Link
US (2) US20020052025A1 (fr)
EP (1) EP1355944B1 (fr)
AT (1) ATE454400T1 (fr)
AU (1) AU2001266767A1 (fr)
CA (1) CA2412183C (fr)
DE (1) DE60141045D1 (fr)
WO (1) WO2002006344A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006344A2 (fr) * 2000-06-08 2002-01-24 Baylor College Of Medicine Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique
US20050187153A1 (en) * 2001-06-08 2005-08-25 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer, autoimmunity and infectious disease
WO2005002413A2 (fr) * 2003-07-01 2005-01-13 Bar Ilan University Methodes et reactifs pour le diagnostic et le traitement de gliomes
US7824685B2 (en) * 2004-01-26 2010-11-02 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer
WO2007099529A1 (fr) 2006-02-28 2007-09-07 Sandisk Il Ltd Synchronisation de fichiers par mise en signet
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
US20130156777A1 (en) * 2011-09-12 2013-06-20 Raymond A. Koski Glipr1 inhibitors and therapeutic uses thereof
US10256831B2 (en) 2016-09-21 2019-04-09 Analog Devices Global Method and apparatus to reduce effect of dielectric absorption in SAR ADC
US20200048319A1 (en) * 2018-08-07 2020-02-13 Glipper Oncology Research, Inc. Compositions of GLIPR Fusion Proteins and Methods for the Treatment of Prostate Cancer
CA3136964A1 (fr) 2019-04-30 2020-11-05 Polaris Industries Inc. Vehicule comprenant un bloc d'entrainement d'essieu
US12415394B2 (en) 2019-04-30 2025-09-16 Polaris Industries, Inc. Vehicle
US12187127B2 (en) 2020-05-15 2025-01-07 Polaris Industries Inc. Off-road vehicle
USD947732S1 (en) 2020-08-04 2022-04-05 Polaris Industries Inc. Hood for an off-road vehicle
MX2023006716A (es) 2022-06-13 2023-12-14 Polaris Inc Tren de potencia para vehiculo utilitario.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789200A (en) * 1996-10-31 1998-08-04 Smithkline Beecham Corporation Human ETS family member, ELF3
US5856130A (en) * 1996-12-26 1999-01-05 Incyte Pharmaceuticals, Inc. Human pathogenesis-related protein
WO2000052204A2 (fr) * 1999-02-22 2000-09-08 Orntoft Torben F Expression genique dans les tumeurs de la vessie
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030219743A1 (en) * 2000-05-18 2003-11-27 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002006344A2 (fr) 2000-06-08 2002-01-24 Baylor College Of Medicine Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique
IT1318937B1 (it) * 2000-09-27 2003-09-19 Getters Spa Metodo per la produzione di dispositivi getter porosi con ridottaperdita di particelle e dispositivi cosi' prodotti
US20030119009A1 (en) * 2001-02-23 2003-06-26 Stuart Susan G. Genes regulated by MYCN activation
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US20030144494A1 (en) * 2001-10-02 2003-07-31 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2004111200A2 (fr) 2003-06-09 2004-12-23 Baylor College Of Medicine Compositions du type rtvp-glipr et methodes de detection, de traitement et de prevention du cancer de la prostate
WO2005002413A2 (fr) 2003-07-01 2005-01-13 Bar Ilan University Methodes et reactifs pour le diagnostic et le traitement de gliomes

Also Published As

Publication number Publication date
US20020052025A1 (en) 2002-05-02
DE60141045D1 (de) 2010-02-25
EP1355944A2 (fr) 2003-10-29
US20040009508A1 (en) 2004-01-15
CA2412183A1 (fr) 2002-01-24
US7645452B2 (en) 2010-01-12
WO2002006344A3 (fr) 2003-08-21
ATE454400T1 (de) 2010-01-15
WO2002006344A2 (fr) 2002-01-24
EP1355944B1 (fr) 2010-01-06
CA2412183C (fr) 2010-08-03

Similar Documents

Publication Publication Date Title
Kwabi-Addo et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer
US9944951B2 (en) Chromosome 3p21.3 genes are tumor suppressors
EP1355944B1 (fr) Compositions et procedes a base des proteines vespides et pathogenes associees a des proteines specifiques aux testicules (rtvp) pour le traitement du cancer prostatique
CN102836420B (zh) 包含mda-7的组合物和方法
CA2238829A1 (fr) Methodes et compositions pour diagnostiquer et traiter des cancers
US6545139B1 (en) DNA sequence encoding the p99 gene and kits for the detection of neoplasia
AU2001273337A1 (en) Chromosome 3p21.3 genes are tumor suppressors
Mukhopadhyay et al. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53
WO2006098074A1 (fr) Agent inducteur d’apoptose pour cellule cancereuse de la prostate
US7824685B2 (en) RTVP based compositions and methods for the treatment of prostate cancer
US20050187153A1 (en) RTVP based compositions and methods for the treatment of prostate cancer, autoimmunity and infectious disease
JP2002504562A (ja) 腫瘍関連抗原７９１Ｔｇｐ７２
KR100454871B1 (ko) 사이모신 β- 10을 고형악성종양의 유전자 치료에사용하는 용도
AU2006222760B2 (en) Chromosome 3p21.3 genes are tumor suppressors
CN119700934A (zh) Meis1在制备子宫内膜异位症治疗剂中的应用及其制备的治疗剂
HK1180218B (en) Methods and compositions involving mda-7
CA2275438A1 (fr) Methodes ameliorees de transduction cellulaire
AU3084199A (en) Compositions and methods for the treatment and prevention of metastatic disorders

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application